The immune development in a child born to a cyclosporin A-treated woman with systemic lupus erythematosus/polymyositis.
The case of a woman affected by an overlap syndrome systemic lupus erythematosus/polymyositis (PM), who presented with active myositis at the start of the pregnancy, is reported. Therapy with cyclosporin, corticosteroids, hydroxychloroquine and high-dose intravenous immunoglobulin induced a progressive remission of clinical and laboratory signs of myositis. At 33 weeks of gestation, after a premature pre-term rupture of membrane, a male child was delivered. Although premature, and small for gestational age, he had a normal growth, and did not show any clinical sign suggestive of immune deficiency. Lymphocyte phenotypical and functional studies, as well as response to vaccination, were also normal.
Airò
P
P
Division of Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy. cattaneo@master.cci.unibs.it
Antonioli
C M
CM
Motta
M
M
Faden
D
D
Chirico
G
G
Cattaneo
R
R
Tincani
A
A
D000293:Adolescent; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007107:Immune System / Q000002:abnormalities* / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007231:Infant, Newborn; D007234:Infant, Premature; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D017285:Polymyositis / Q000188:drug therapy / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000276:immunology; D011297:Prenatal Exposure Delayed Effects
D007166:Immunosuppressive Agents; D016572:Cyclosporine